Latest news with #StereotaxisInc
Yahoo
13-05-2025
- Business
- Yahoo
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.09, delivering a surprise of -80%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Stereotaxis , which belongs to the Zacks Medical - Instruments industry, posted revenues of $7.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.74%. This compares to year-ago revenues of $6.88 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Stereotaxis shares have lost about 6.6% since the beginning of the year versus the S&P 500's decline of -3.8%. While Stereotaxis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Stereotaxis: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.07 on $7.95 million in revenues for the coming quarter and -$0.26 on $34 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Lucid Diagnostics Inc. (LUCD), has yet to report results for the quarter ended March 2025. The results are expected to be released on May 14. This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +57.1%. The consensus EPS estimate for the quarter has been revised 40% higher over the last 30 days to the current level. Lucid Diagnostics Inc.'s revenues are expected to be $1.3 million, up 30% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stereotaxis Inc. (STXS) : Free Stock Analysis Report Lucid Diagnostics Inc. (LUCD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
23-03-2025
- Business
- Yahoo
Nvidia's Support Boosts Stereotaxis (STXS) in Advancing Robotic Surgery
We recently compiled a list of the Top 8 AI News Updates Investors Shouldn't Miss. In this article, we are going to take a look at where Stereotaxis Inc. (NYSE:STXS) stands against the other AI stocks. On March 19th, the stock market bounced back after the US Federal Reserve kept interest rates unchanged at 4.25% to 4.5%. The Fed also anticipated two rate cuts this year despite elevated inflation. The S&P 500 index was up over 1%, while the Nasdaq Composite jumped by well over 200 points. The rally was led by the magnificent seven stocks after weeks of market declines amid trade wars and disappointing economic data. Elsewhere, AI continues to transform industries and individual lives, from AI nurses reshaping hospital care to schools reporting that students are learning faster and more effectively with AI. Furthermore, AngelList CEO Avlok Kohli claimed that all software companies are AI companies now. 'The enthusiasm into AI actually carries over into everything, which effectively impacts all startups,' said Kohli when asked if investors are as excited about emerging startups outside of AI. Meanwhile, security risks surrounding AI continue to loom. Computer scientist and AI pioneer Fei-Fei Li co-authored a report suggesting that lawmakers should consider AI risks that 'have not yet been observed in the world' when devising AI regulations. The report highlighted that the novel risks posed by AI could require legislation that compels AI developers to publicly report their safety tests and security protocols. We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey's Q4 2024 database of over 1000 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A robotic arm assembling delicate surgical tools in a clean room environment. Stereotaxis Inc. (NYSE:STXS) engages in discovering, designing, and delivering innovative surgical robotic systems, instruments, and information systems for minimally invasive endovascular surgeries. Its robotic systems help physicians operate with precision and safety, boosting productivity and connectivity in the operating room. The company is focusing on enhancing its robotic systems and the operating room environments using AI, automation, and data integration. On March 19th, Stereotaxis (NYSE:STXS) announced that Nvidia Corp. (NASDAQ:NVDA) accepted the company into the Nvidia Connect program. The program assists members with Nvidia's software development resources and frameworks. 'We greatly appreciate the support of NVIDIA in our efforts to pioneer endovascular robotics and take the technology to new incredible heights. The combination of robotics' mechanistic benefits – precision, safety, stability – with the promise of AI innovations will dramatically transform what is possible in treating patients. We are excited for the path ahead of us.' Overall, STXS ranks 8th on our list of top AI news updates investors shouldn't miss. While we acknowledge the potential of STXS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than STXS but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at .
Yahoo
04-03-2025
- Business
- Yahoo
Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
Fourth Quarter Revenue: $6.3 million, a 39% increase year-over-year. System Revenue (Q4 2024): $1.4 million, up from $0.1 million in Q4 2023. Recurring Revenue (Q4 2024): $4.9 million, compared to $4.5 million in Q4 2023. Full-Year 2024 Revenue: $26.9 million, slightly up from $26.8 million in 2023. Full-Year System Revenue: $8.6 million, compared to $8.7 million in 2023. System Backlog (Start of 2025): $15.2 million. Full-Year Recurring Revenue: $18.3 million, up from $18 million in 2023. Gross Margin (Q4 2024): Approximately 51%. Gross Margin (Full-Year 2024): Approximately 54%. Operating Expenses (Q4 2024): $10.8 million, including $2.5 million in non-cash stock compensation and $1.1 million non-cash mark-to-market adjustment. Adjusted Operating Expenses (Q4 2024): $7.2 million. Operating Loss (Q4 2024): $7.6 million. Net Loss (Q4 2024): $7.5 million. Adjusted Operating Loss (Q4 2024): $4 million. Adjusted Net Loss (Q4 2024): $3.8 million. Free Cash Flow (Q4 2024): Positive $1.3 million. Free Cash Flow (Full-Year 2024): Negative $8.5 million. Cash and Cash Equivalents (End of 2024): $12.4 million, with no debt. Warning! GuruFocus has detected 9 Warning Signs with STXS. Release Date: March 03, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Stereotaxis Inc (STXS) announced significant milestones with FDA submissions for key catheter innovations, indicating progress in their strategic transformation. The company reported a 39% year-over-year increase in fourth-quarter revenue, totaling $6.3 million, showcasing strong financial performance. Stereotaxis Inc (STXS) received European CE mark approval for the GenesisX robot and MAGiC ablation catheter, with plans for commercial launch in Europe. The strategic acquisition of APT has enhanced Stereotaxis Inc (STXS)'s in-house catheter development and manufacturing capabilities. The company is expanding its product portfolio with the introduction of the EMAGIN vascular catheter, targeting multiple new endovascular indications. Stereotaxis Inc (STXS) faces challenges with FDA regulatory approval timelines, particularly for the MAGiC catheter in the US. The company has a system backlog of $15.2 million, indicating potential delays in revenue recognition. Recurring revenue growth is impacted by catheter shortages from Johnson & Johnson, affecting overall financial performance. Operating expenses increased due to non-cash stock compensation and acquisition-related costs, impacting profitability. The macroeconomic environment and anti-corruption campaigns in China present headwinds for commercial efforts in the region. Q: Can you provide more details on the MAGiC catheter's approval process in the US and what needs to happen for a second-half approval? A: David Fischel, Chairman and CEO, explained that they are enrolling patients in Europe to meet FDA's unmet medical need criteria. The FDA is conducting a detailed review of the PMA submission, and Stereotaxis is responding to questions and refining the submission. There might be an audit of the manufacturing facility in Germany, but it's not certain. The FDA is working collaboratively to ensure a thorough and timely review. Q: How will the MAGiC Sweep high-density mapping catheter fit into the broader ecosystem, and how might it affect your relationship with Abbott? A: David Fischel stated that the MAGiC Sweep will be used in the majority of robotic procedures, allowing physicians to perform high-density mapping robotically. This development is part of a broader strategy and has been communicated to partners like Abbott, with no concerns about its impact on existing relationships. Q: Can you clarify the system revenue guidance for 2025, given the GenesisX launch in Europe and China? A: David Fischel noted that the guidance is conservative, focusing on transitioning existing backlog into revenue. The unpredictability of sales in China and the timing of revenue recognition contribute to the cautious outlook. The guidance does not assume significant sales in China and reflects modest expectations for GenesisX. Q: What is the expected timeline for GenesisX commercial approval in the US? A: David Fischel mentioned that they are responding to FDA questions and expect GenesisX approval before the compatible catheters are approved. They anticipate having at least one compatible catheter approved in the third quarter, allowing for a commercial launch in the US. Q: What is the strategic importance of the EMAGIN vascular guidance catheter, and how do you plan to prioritize its applications? A: David Fischel emphasized that while short-term revenue expectations for EMAGIN are modest, its strategic value is substantial. The catheter will enable the robot to become a multi-specialty platform, expanding its use into neurointervention, interventional cardiology, and oncology. The focus will be on demonstrating clinical utility in these areas to expand the robot's value proposition. Q: Is there any capacity constraint related to the MAGiC catheter, and how are you addressing it? A: David Fischel confirmed that they are ramping up manufacturing in Europe and working through administrative processes with hospitals. The goal is to ensure a steady supply as they scale up sales throughout the year. Q: How frequently do you expect the MAGiC Sweep mapping catheter to be used, and what is the expected impact on catheter sales? A: David Fischel anticipates that the MAGiC Sweep will be used in a significant portion of procedures, potentially increasing the pool of robotic users. The combined sales of MAGiC and MAGiC Sweep are expected to increase disposable revenue per procedure by more than fivefold. Q: What is included in the guidance for the MAGiC launch in Europe and the US? A: David Fischel clarified that the guidance includes $3 million to $4 million related to the MAGiC launch in Europe, with no revenue from a potential US launch included due to uncertainty in approval timelines. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
